A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Phase of Trial: Phase III
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Allergan
- 22 Jan 2018 Planned End Date changed from 30 Oct 2020 to 5 Jul 2020.
- 22 Jan 2018 Planned primary completion date changed from 30 Oct 2020 to 5 Jul 2020.
- 01 Nov 2017 According to an Allergan media release, the company expects to begin dosing patients in the coming weeks.